Xiangyu Zhong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiangyu Zhong has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Jianjun Gao
General Surgery Department The 2nd Affiliated Hospital of Harbin Medical University 148 Baojian Street Harbin Heilongjiang Province 150086 China
4 shared publicationsWujiang Shi
General Surgery Department The 2nd Affiliated Hospital of Harbin Medical University 148 Baojian Street Harbin Heilongjiang Province 150086 China
4 shared publicationsXinlei Zou
General Surgery Department The 2nd Affiliated Hospital of Harbin Medical University 148 Baojian Street Harbin Heilongjiang Province 150086 China
4 shared publicationsCanghai Guan
General Surgery Department, The 2nd Affiliated Hospital of Harbin Medical University, 148 Baojian Street, Harbin 150086, Heilongjiang Province, China; The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry of Education, 148 Baojian Street, Harbin 150086, Heilongjiang, China
3 shared publicationsChengru Yang
General Surgery Department The 2nd Affiliated Hospital of Harbin Medical University 148 Baojian Street Harbin Heilongjiang Province 150086 China
2 shared publicationsShaowu Bi
General Surgery Department The 2nd Affiliated Hospital of Harbin Medical University 148 Baojian Street Harbin Heilongjiang Province 150086 China
2 shared publications
Latest Publications
- Open Access
- 21 January 2025
- Published by Wiley in Advanced Science
- Vol. 12 (10) , e2409173
A Novel 167‐Amino Acid Protein Encoded by CircPCSK6 Inhibits Intrahepatic Cholangiocarcinoma Progression via IKBα Ubiquitination
Intrahepatic cholangiocarcinoma (ICC), a formidable challenge in oncology, demands innovative biomarkers and therapeutic targets. This research highlights the importance of the circular RNA (circRNA) circPCSK6 and its peptide derivative circPCSK6‐167aa in ICC. CircPCSK6 is significantly downregulated in both ICC patients and mouse primary ICC models, and its lower expression is linked to adverse prognosis, highlighting its pivotal role in ICC pathogenesis. Functionally, this study elucidates the regulatory effect of circPCSK6‐167aa on IκBα ubiquitination within the NF‐κB pathway, which is mediated by its competitive binding to the E3 ligase RBBP6. This complex interaction leads to reduced activation of the NF‐κB pathway, thereby curbing tumor cell proliferation, migration, invasion, stemness, and hepatic‐lung metastasis in vivo. This groundbreaking discovery expands the understanding of circRNA‐driven tumorigenesis through atypical signaling pathways. Additionally, this investigation identified EIF4A3 as a detrimental regulator of circPCSK6, exacerbating ICC malignancy. Importantly, by leveraging patient‐derived xenograft (PDX), organoids, and organoid‐derived PDX models, higher levels of circPCSK6‐167aa enhance sensitivity to gemcitabine, indicating its potential to improve the effectiveness of chemotherapy. These insights emphasize the therapeutic promise of targeting circPCSK6‐167aa, offering vital biological insights and clinical directions for developing cutting‐edge therapeutic approaches, thus revealing innovative strategies and targets for future treatments.
- 21 January 2025
- Published by Wiley in Advanced Science
- Vol. 12 (10) , e2409173
Open AccessA Novel 167‐Amino Acid Protein Encoded by CircPCSK6 Inhibits Intrahepatic Cholangiocarcinoma Progression via IKBα Ubiquitination
Intrahepatic cholangiocarcinoma (ICC), a formidable challenge in oncology, demands innovative biomarkers and therapeutic targets. This research highlights the importance of the circular RNA (circRNA) circPCSK6 and its peptide derivative circPCSK6‐167aa in ICC. CircPCSK6 is significantly downregulated in both ICC patients and mouse primary ICC models, and its lower expression is linked to adverse prognosis, highlighting its pivotal role in ICC pathogenesis. Functionally, this study elucidates the regulatory effect of circPCSK6‐167aa on IκBα ubiquitination within the NF‐κB pathway, which is mediated by its competitive binding to the E3 ligase RBBP6. This complex interaction leads to reduced activation of the NF‐κB pathway, thereby curbing tumor cell proliferation, migration, invasion, stemness, and hepatic‐lung metastasis in vivo. This groundbreaking discovery expands the understanding of circRNA‐driven tumorigenesis through atypical signaling pathways. Additionally, this investigation identified EIF4A3 as a detrimental regulator of circPCSK6, exacerbating ICC malignancy. Importantly, by leveraging patient‐derived xenograft (PDX), organoids, and organoid‐derived PDX models, higher levels of circPCSK6‐167aa enhance sensitivity to gemcitabine, indicating its potential to improve the effectiveness of chemotherapy. These insights emphasize the therapeutic promise of targeting circPCSK6‐167aa, offering vital biological insights and clinical directions for developing cutting‐edge therapeutic approaches, thus revealing innovative strategies and targets for future treatments.
- Open Access
- 31 August 2024
- Published by Elsevier in Molecular Metabolism
- Vol. 89, 102022
Polyribonucleotide nucleotidyltransferase 1 participates in metabolic-associated fatty liver disease pathogenesis by affecting lipid metabolism and mitochondrial homeostasis
- 31 August 2024
- Published by Elsevier in Molecular Metabolism
- Vol. 89, 102022
Open AccessPolyribonucleotide nucleotidyltransferase 1 participates in metabolic-associated fatty liver disease pathogenesis by affecting lipid metabolism and mitochondrial homeostasis
- Open Access
- 17 July 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1222719
Tertiary lymphoid structures in pancreatic cancer: a new target for immunotherapy
Pancreatic cancer (PC) is extremely malignant and shows limited response to available immunotherapies due to the hypoxic and immunosuppressive nature of its tumor microenvironment (TME). The aggregation of immune cells (B cells, T cells, dendritic cells, etc.), which is induced in various chronic inflammatory settings such as infection, inflammation, and tumors, is known as the tertiary lymphoid structure (TLS). Several studies have shown that TLSs can be found in both intra- and peritumor tissues of PC. The role of TLSs in peritumor tissues in tumors remains unclear, though intratumoral TLSs are known to play an active role in a variety of tumors, including PC. The formation of intratumoral TLSs in PC is associated with a good prognosis. In addition, TLSs can be used as an indicator to assess the effectiveness of treatment. Targeted induction of TLS formation may become a new avenue of immunotherapy for PC. This review summarizes the formation, characteristics, relevant clinical outcomes, and clinical applications of TLSs in the pancreatic TME. We aim to provide new ideas for future immunotherapy of PC.
- 17 July 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1222719
Open AccessTertiary lymphoid structures in pancreatic cancer: a new target for immunotherapy
Pancreatic cancer (PC) is extremely malignant and shows limited response to available immunotherapies due to the hypoxic and immunosuppressive nature of its tumor microenvironment (TME). The aggregation of immune cells (B cells, T cells, dendritic cells, etc.), which is induced in various chronic inflammatory settings such as infection, inflammation, and tumors, is known as the tertiary lymphoid structure (TLS). Several studies have shown that TLSs can be found in both intra- and peritumor tissues of PC. The role of TLSs in peritumor tissues in tumors remains unclear, though intratumoral TLSs are known to play an active role in a variety of tumors, including PC. The formation of intratumoral TLSs in PC is associated with a good prognosis. In addition, TLSs can be used as an indicator to assess the effectiveness of treatment. Targeted induction of TLS formation may become a new avenue of immunotherapy for PC. This review summarizes the formation, characteristics, relevant clinical outcomes, and clinical applications of TLSs in the pancreatic TME. We aim to provide new ideas for future immunotherapy of PC.
- 20 April 2023
- Published by Elsevier in Clinica Chimica Acta
- Vol. 544, 117360
Exosomal miRNAs in the microenvironment of pancreatic cancer
- 20 April 2023
- Published by Elsevier in Clinica Chimica Acta
- Vol. 544, 117360
Exosomal miRNAs in the microenvironment of pancreatic cancer